Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01907867
Recruitment Status : Completed
First Posted : July 25, 2013
Last Update Posted : February 20, 2017
Sponsor:
Information provided by (Responsible Party):
MerLion Pharmaceuticals GmbH

Brief Summary:
This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted.

Condition or disease Intervention/treatment Phase
Safety and Tolerability Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers
Study Start Date : January 2012
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Arm Intervention/treatment
Experimental: Cohort 1

Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.

Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).

Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples.

Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Experimental: Cohort 2

Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.

Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).

Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.

Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples.

Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Experimental: Cohort 3

Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.

Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).

Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.

Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples.

Drug: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days



Primary Outcome Measures :
  1. To assess the safety and tolerability of orally administered finafloxacin in healthy subjects. [ Time Frame: Day 3 ]
    The assessment of safety will be based primarily on the frequency of adverse events, clinical laboratory assessments (chemistry, hematology, and urinalysis), physical examinations, vital signs, and 12-lead ECGs. Other safety data will be summarized as appropriate. The data will be presented in descriptive manner.


Secondary Outcome Measures :
  1. Pharmacokinetic (PK) profile in plasma and epithelial lining fluid (ELF) [ Time Frame: Day 3 ]
    To assess the pharmacokinetic (PK) profile in plasma and epithelial lining fluid (ELF) of finafloxacin after single and multiple doses administered orally in healthy subjects;

  2. Comparison of bronchial ELF PK profiles with alveolar ELF PK profiles. [ Time Frame: Day 3 ]
    To compare the bronchial ELF PK profiles obtained by bronchoscopic microsampling (BMS) techniques to alveolar ELF PK profiles obtained by bronchoalveolar lavage (BAL).


Other Outcome Measures:
  1. Intracellular concentrations of finafloxacin in alveolar macrophages (AMs). [ Time Frame: Day 3 ]
    To assess the intracellular concentrations of finafloxacin as measured in alveolar macrophages (AMs) obtained by BAL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to provide written informed consent;
  2. Age ≥18 years and ≤55 years;
  3. Male or female healthy volunteer;
  4. Body mass index (BMI) ≥18.0 kg/m2 and ≤30.0 kg/m2 and a body weight

    ≥48 kg and ≤100 kg;

  5. Women of childbearing potential must have a negative urine pregnancy test confirmed at Screening before study enrollment, must not be breastfeeding, and must use an effective method of contraception for at least 1 month before enrollment and through 3 months following completion of the study:

    • A woman of childbearing potential is defined as any female subject who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as women over the age of 50 who have been amenorrheic for at least 12 consecutive months);
    • Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier method (diaphragm, condoms, spermicides) to prevent pregnancy, or whose partner is sterile (e.g. vasectomy) should be considered to be of childbearing potential;
  6. If a male subject's sexual partner is of childbearing potential, the male subject must acknowledge that they are using an acceptable method of contraception (defined above) from the first dose of study drug until 3 months from last dosing occasion to prevent pregnancy;
  7. Expectation, in the judgment of the Investigator, that the subject will complete all study activities; and
  8. Willing to comply with all the study activities and procedures throughout the duration of the study.

Exclusion Criteria:

  1. Known chronic medical conditions, including any respiratory condition such as asthma or chronic obstructive pulmonary disease, or cardiovascular conditions such as hypertension or coronary artery disease;
  2. Prolongation of corrected QT interval (QTcB) at rest, where the mean QTcB interval is >500 msec based on triplicate ECG at Screening;
  3. Use of tobacco products within 6 months of Screening;
  4. Women who are pregnant or breastfeeding;
  5. Receipt of any investigational medication during the last month (30 days or 5 half-lives, whichever is longer) prior to enrollment;
  6. Prior exposure to finafloxacin;
  7. Use of any concomitant medication (including over-the-counter drugs, vitamins, and antacids) within 7 days prior to study drug administration and during the study (acetaminophen is allowed);
  8. Any disorder that may interfere with the evaluation of study drug;
  9. Known hypersensitivity to finafloxacin or to any other fluoroquinolone;
  10. Donated any blood, plasma, or platelets in the 3 months prior to enrollment or on more than 2 occasions within the 12 months preceding the first dose of study drug;
  11. Known history of tendon rupture or tendonitis;
  12. A positive urine drug screen or breath alcohol test result at Screening or enrollment;
  13. Known to have viral hepatitis, or are positive for the Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody, or are positive for Human Immunodeficiency Virus (HIV) antibodies;
  14. Clinically significant abnormal laboratory values at Screening or enrollment;
  15. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol;
  16. An employee of the Investigator or study site with direct involvement in the proposed study or other studies under the direction of the Investigator or study site, or a family member of the site employee or the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01907867


Locations
Layout table for location information
United States, Arizona
Pulmonary Associates, PA
Phoenix, Arizona, United States, 85006
Sponsors and Collaborators
MerLion Pharmaceuticals GmbH
Investigators
Layout table for investigator information
Principal Investigator: Mark H. Gottfried, MD Pulmonary Associates, PA
Layout table for additonal information
Responsible Party: MerLion Pharmaceuticals GmbH
ClinicalTrials.gov Identifier: NCT01907867    
Other Study ID Numbers: FINA-008
First Posted: July 25, 2013    Key Record Dates
Last Update Posted: February 20, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Finafloxacin
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents